Andrea Necchi, MD

home / authors / andrea-necchi-md

Articles

Andrea Necchi, MD

Dr Necchi on the Efficacy of TAR-200 Monotherapy in BCG-Unresponsive NMIBC

Andrea Necchi, MD
January 4th 2024

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Read More

Andrea Necchi, MD, medical oncologist, IRCCS San Raffaele Hospital and Scientific Institute, associate professor, Vita-Salute San Raffaele University, Milan, Italy,

Dr. Necchi on Key Results From Cohort B of the KEYNOTE-057 Trial in MIBC

Andrea Necchi, MD
February 17th 2023

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

Read More

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

Andrea Necchi, MD
November 17th 2017

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data